811 related articles for article (PubMed ID: 32495269)
21. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
23. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
24. Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.
Man J; Millican J; Mulvey A; Gebski V; Hui R
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34084999
[TBL] [Abstract][Full Text] [Related]
25. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
26. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
27. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
Zhang Q; Wang W; Yuan Q; Li L; Wang YC; Chi CZ; Xu CH
Cancer Chemother Pharmacol; 2022 Jan; 89(1):1-9. PubMed ID: 34821962
[TBL] [Abstract][Full Text] [Related]
28. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Boudou-Rouquette P; Arrondeau J; Gervais C; Durand JP; Fabre E; De Percin S; Villeminey CV; Piketty AC; Rassy N; Ulmann G; Damotte D; Mansuet-Lupo A; Giraud F; Alifano M; Wislez M; Alexandre J; Jouinot A; Goldwasser F
EBioMedicine; 2021 Nov; 73():103630. PubMed ID: 34688030
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Cui Q; Li W; Wang D; Wang S; Yu J
World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
[TBL] [Abstract][Full Text] [Related]
31. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis.
Shen X; Huang S; Xiao H; Zeng S; Liu J; Ran Z; Xiong B
Eur J Hosp Pharm; 2023 Jan; 30(1):3-8. PubMed ID: 34497128
[TBL] [Abstract][Full Text] [Related]
35. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
36. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
39. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
40. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]